Audentes Therapeutics (BOLD) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Audentes Therapeutics (BOLD) PT Raised to $32 at Evercore ISI
August 7, 2018 3:01 PM EDTEvercore ISI raised its price target on Audentes Therapeutics (NASDAQ: BOLD) to $32.00 (from $30.00) while maintaining a In Line rating.
... MoreAudentes Therapeutics (BOLD) Announces Update on ASPIRO Phase 1/2 Clinical Trial of AT132 in Patients with X-Linked Myotubular Myopathy
August 7, 2018 6:23 AM EDTAudentes Therapeutics, Inc. (NASDQ: BOLD) today reported its financial results for the second quarter ended June 30, 2018 and provided an update on ASPIRO, the phase 1/2 clinical trial of AT132 in patients with X-Linked Myotubular Myopathy (XLMTM), including muscle biopsy results from the first three patients treated in the study and the week 24 efficacy analysis for Patient 3.
"We're very pleased with continued clinical progress in ASPIRO, and in particular the results of the muscle biopsy data from the first three ASPIRO patients, which show unprecedented levels of tissue transduction and protein expression from a systemically... More
